🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Krystal Biotech, Inc. KRYS R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.krystalbio.com
Company Profile ↓
$311.50
+108.58% 1Y
Mkt Cap$9.22B
P/E38.99
P/B7.33
52W High$378.15
52W Low$137.46
Book Value$45.92
EPS (TTM)$7.99

Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.1%, reflecting efficient use of shareholder capital.

Healthy Margins

Maintains a net profit margin of 54.8%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $389.13M (+33.9% YoY); net profit $204.83M.
  • Trailing 12 Months Year-on-year growth — revenue +24.1%, earnings +38.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:24.10%

Compounded Profit Growth

5 Years:-
1 Year:38.80%

Stock Price Performance

1 Year:+108.58%
6 Months:+14.30%
3 Months:-11.46%
1 Month:-9.70%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 72% of range
$137.46 $378.15
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)37.75 · Neutral
Price Performance
1M-9.70%
3M-11.46%
6M+14.30%
1Y+108.58%
Valuation vs Sector

P/E of 38.99 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.1%.
  • Excellent profit margin of 54.8%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
38.99
Industry PE
25.45
Forward P/E
33.15
PEG Ratio
-
Book Value
$45.92
Price to Book
7.33
P/S
22.62
EV/EBITDA
45.80
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
24.10%
Earnings (YoY)
38.80%

Profitability & Returns

ROCE
13.10%
ROE
20.12%
ROA
9.37%
Profit Margin
54.82%
Op Margin
49.00%
Gross Margin
94.64%
EPS (Latest Qtr)
$1.79
EPS (TTM)
$7.99

Balance Sheet & Liquidity

Debt/Equity
0.65
Quick Ratio
7.73
Current Ratio
8.32
Debt
$8.85M
Total Assets
$1.50B
Current Assets
$1.02B
Working Capital
$921.66M

Ownership

Promoter Holding
10.66%
Chg in Prom Hold
-0.17%
FII / Inst Holding
102.44%
Chg in FII Hold
-0.09%

Financial Snapshot

Enterprise Value
$9.22B
Total Revenue (TTM)
$440.48M
EBITDA
$199.29M
Free Cash Flow
$151.74M
Operating Cash Flow
$272.34M
Shares Outstanding
29.60M
Gross Margin
94.64%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KRYS Krystal Biotech, Inc. R2KR3KPHARMA 311.50 38.99 $9.22B 0.00% 13.10% 20.12% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------------0008.56M45.25M70.28M83.84M88.18M96.04M97.80M116.36M119.22M
Operating Income -322.00K-465.00K-715.00K-2.09M-2.28M-2.45M-2.97M-4.69M-5.89M-5.34M-5.95M-6.95M-9.68M-14.35M-16.39M-15.65M-50.22M-28.75M-31.45M-48.82M-38.05M-25.99M-6.68M8.57M22.47M36.25M39.31M41.37M53.69M58.42M
Net Income -322.00K-494.00K-759.00K-5.27M-2.15M-2.28M-2.75M-4.11M-5.35M-4.27M-5.34M-6.83M-9.61M-15.81M-16.36M-15.59M-49.97M-28.11M-29.85M-45.30M-33.21M80.75M932.00K15.57M27.18M35.73M38.33M79.36M55.93M54.77M
Diluted EPS ------------0.37-0.49-0.74-0.74-0.70-1.99-1.10-1.17-1.76-1.252.790.030.530.911.201.292.661.831.79
R&D Expense 241.00K319.00K446.00K1.35M1.52M1.52M1.91M3.17M4.22M3.88M3.52M3.64M5.10M6.20M6.59M6.08M9.31M10.89M11.52M12.29M12.14M10.63M10.96M15.58M13.51M14.26M14.41M14.59M15.33M14.52M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -----0050.70M290.51M389.13M
Operating Income -1.14M-4.77M-11.92M-22.08M-33.00M-68.28M-145.20M-109.62M65.75M161.29M
Net Income -1.15M-7.92M-10.89M-19.09M-32.17M-69.57M-139.97M10.93M89.16M204.83M
Diluted EPS -----1.71-3.13-5.490.393.006.84
R&D Expense 741.00K3.21M7.76M15.62M17.94M27.88M42.46M46.43M53.58M58.05M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Aug 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 2.18M-50.11M116.12M209.02M310.84M-558.45M818.36M1.06B1.33B
Current Assets -------383.78M587.91M742.04M1.02B
Cash & Equivalents 1.92M-49.59M103.67M187.51M268.27M-161.90M358.33M344.87M496.30M
Inventory -------06.99M26.51M40.48M
Receivables -------042.04M104.75M127.42M
Total Liabilities 1.89M-640.00K2.89M6.11M18.76M-36.22M39.71M109.46M114.23M
Current Liabilities 43.00K-640.00K2.60M3.33M15.45M-28.85M33.09M102.00M102.94M
Long Term Debt -4.25M---------
Total Debt -------8.93M8.09M7.26M9.34M
Total Equity 289.00K-49.47M113.23M202.91M292.08M-522.23M778.64M946.38M1.22B
Shares Outstanding -------25.76M28.24M28.79M29.19M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---9.45M-18.69M-26.08M-47.94M-100.57M-88.80M123.42M200.87M
Investing Cash Flow ---10.32M-4.99M-11.18M-226.77M-114.08M82.64M-163.44M-58.42M
Financing Cash Flow --73.85M107.53M118.02M347.69M35.35M202.75M27.01M8.71M
Capital Expenditure -15.00K-210.00K-2.23M-6.40M-14.84M-68.34M-52.98M-11.80M-4.24M-11.95M
Free Cash Flow ---11.68M-25.09M-40.93M-116.27M-153.55M-100.60M119.18M188.91M

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------
Operating Margin % --------216.2%22.6%41.5%
Net Margin % -------21.6%30.7%52.6%
ROE % -397.9%-16.0%-9.6%-9.4%-11.0%--26.8%1.4%9.4%16.8%
ROCE % -53.4%-9.6%-10.5%-10.7%-11.2%--27.4%-14.0%6.9%13.1%

Shareholding Pattern

Insiders
10.66%
Institutions
102.44%
Public Float
114.66%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 14.93% 4.42M $1.47B
2 Blackrock Inc. 14.13% 4.18M $1.39B
3 Avoro Capital Advisors LLC 9.76% 2.89M $957.98M
4 Vanguard Portfolio Management LLC 5.32% 1.57M $522.25M
5 State Street Corporation 4.56% 1.35M $448.06M
6 Vanguard Capital Management LLC 4.19% 1.24M $411.38M
7 Soleus Capital Management, L.P. 3.17% 939.25K $311.47M
8 Capital World Investors 2.63% 777.84K $257.94M
9 Geode Capital Management, LLC 2.36% 698.99K $231.79M
10 Price (T.Rowe) Associates Inc 2.32% 687.40K $227.95M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KRYS

Google News hu, 22 Oct 2026

Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNeFhwckdqWk45TGhtRndtUF9IVk5YX2RhbkhTQ1BWLVBlMGJ0WHdjRDU4S1h5YUlVZUZHWXFvOFd6NXBQRlFtZ0RGVHlVUFZrT3Y4anI0ZlR3aHJudXpHZFhocDE4am1iZ3lxbmJQU3d5a2xQczRiaEVKNkR2WkNKRjRSVVlTQkphaVJCSX…

Google News Fri, 23 Oct 2026

Krystal Biotech, Inc. Estimates – NASDAQ:KRYS - TradingView

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5fbEdwYVJtbThzck5rcTE1VXZKcE0ycVpaU2lFckYtVEVmTHVMdGdjbTJPMTdMN2JkQ3JKVXBMQmhkbzFEYVhFbE9zb2Myd3pyeVAyODV2ajBmZEtiUWt5MjBreGt2eTRtUWRMdzlNRUQ4blFOc1JwUA?oc=5" target="_blank">Kryst…

Google News Fri, 23 Oct 2026

KRYS 261120 175.00C (KRYS261120C175000) Stock Options Chain | Quotes & News - Moomoo

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9adzRPLVl3OGc0b19lY2VoUHBXelRtcDE1V2h6SGFfUUZnN1ZYelVSeGdfaHNjVUJZMWxLMmw5WDlQN1pnYlFXcjBIX2FubWx1RjNCR0YzOGotV19ERVFxOQ?oc=5" target="_blank">KRYS 261120 175.00C (KRYS261120C17500…

Google News hu, 22 Oct 2026

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQZTRYWm84Yjhzbm0zZVpSdHhaa2RmZEJMWHF4Z0NObGtQTjBPVnhaWFVveW44a3BfbDBZSHNkZXhlUUY4Um5RWE9xMUhBdkZIQjY5YmI4QTVEend1ODY1WmpCcUpseGlmWlQ2TEZtcjJYdlFoQXpoVjB1d21NSG44cXNCTGhOX3F1YkN0en…

Google News Fri, 23 Oct 2026

KRYS Nov 2026 540.000 put (KRYS261120P00540000) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9qLWw0bUNuR19mNzQza1dERUh6aGV3d25Xa2FQZkozSGxZQUUwbUVlZ3plakhGZEh5NFZ0UmNTZmZNMUtLVDIyYXUxMXVuY2NDdkhLUDk3VmMyeHk5MGVySXJNOGdwZw?oc=5" target="_blank">KRYS Nov 2026 540.000 put (KR…

Google News Fri, 23 Oct 2026

KRYS Nov 2026 320.000 put (KRYS261120P00320000) stock historical prices and data - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBaLXowaE1iMlNIazJxYzRSeG9oM1BVTGhOUmhfb2dvcmd6Zk9GQ3lsZHdicDRBb3puYlVMME9ZRy1ydTIyS2Z5Um15Mnc2eXl4REN2b2c0TGxYOFBQNDAzNjRhOGNiVVZ1SmF1M2ZkU1Q?oc=5" target="_blank">KRYS Nov 2026 32…

KRYS — Frequently Asked Questions

What is the current share price of Krystal Biotech, Inc. (KRYS)?

As of 2026-10-23 16:27 PDT, Krystal Biotech, Inc. (KRYS) trades at $311.50 on NasdaqGS. Its 52-week range is $137.46 to $378.15.

What is the market capitalisation of KRYS?

Krystal Biotech, Inc. (KRYS) has a market capitalisation of $9.22B on NasdaqGS.

What is the P/E ratio of KRYS?

KRYS trades at a trailing price-to-earnings (P/E) ratio of 38.99. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.33.

What is the return on equity (ROE) of KRYS?

KRYS has a return on equity (ROE) of 20.12%. Its return on capital employed (ROCE) is 13.10%.

Is KRYS a good stock to buy?

This page provides a data-driven analysis of Krystal Biotech, Inc. (KRYS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space